Sugi Predict

Sugi Predict / Compounds / SCHEMBL2348656

SCHEMBL2348656

SCHEMBL2348656

Cc1ccc(-c2ccc(Cl)cc2)cc1C1=C(O)C2(CCOCC2)NC1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 13/20 0.72
▸ ACACA Q13085 13/20 0.72
▸ NTRK1 P04629 2/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ MET P08581 1/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ PRKACA P17612 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ MAP2K2 P36507 1/20 0.37
▸ FLT3 P36888 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ MAP2K1 Q02750 1/20 0.37
▸ MST1R Q04912 1/20 0.37
▸ NTRK3 Q16288 1/20 0.37
▸ NTRK2 Q16620 1/20 0.37
▸ CAMK1D Q8IU85 1/20 0.37
▸ TDP2 O95551 1/20 0.36
▸ MAP4K4 O95819 1/20 0.36
▸ MAPK14 Q16539 3/20 0.34
▸ RAF1 P04049 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2352984 0.92 ACACB (0.61) ACACBACACANTRK1TDP2MAPK14
SCHEMBL2353461 0.92 ACACB (0.83) ACACBACACANTRK1JAK2MET
SCHEMBL2353419 0.90 ACACB (0.77) ACACBACACANTRK1JAK2MET
SCHEMBL6113787 0.89 ACACB (0.73) ACACBACACANTRK1JAK2MET
SCHEMBL12029748 0.89 ACACB (0.58) ACACBACACANTRK1MAPK14RAF1
SCHEMBL6114105 0.89 ACACB (0.75) ACACBACACANTRK1JAK2MET
SCHEMBL2356684 0.89 ACACB (0.75) ACACBACACANTRK1JAK2MET
SCHEMBL2355636 0.89 ACACB (0.75) ACACBACACANTRK1JAK2MET
SCHEMBL2351521 0.88 ACACB (0.61) ACACBACACANTRK1FLT3GSK3B
SCHEMBL2355385 0.88 ACACB (0.80) ACACBACACANTRK1JAK2MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 — — US disclosed
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 — — US disclosed
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 — — US disclosed
EP-2536686-A1 CYCLIC KETO-ENOLS FOR THERAPY Bayer Intellectual Property GmbH (DE) 2012-12-26 — — EP disclosed
US-20120129833-A1 CYCLIC KETOENOLS FOR THERAPY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-24 — — US disclosed
US-20120129833-A1 CYCLIC KETOENOLS FOR THERAPY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-24 — — US disclosed
US-20120129833-A1 CYCLIC KETOENOLS FOR THERAPY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-24 — — US disclosed
WO-2011098433-A1 CYCLIC KETO-ENOLS FOR THERAPY BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-18 — — WO disclosed
WO-2011098433-A1 CYCLIC KETO-ENOLS FOR THERAPY BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY AKR1B1, AKR1C3, AKR1A1 ACACB 310/4885ACACA 541/4885NTRK1 3820/4885
US-20120129833-A1 CYCLIC KETOENOLS FOR THERAPY CYP46A1, LIPC, CYP27A1 ACACB 85/4885ACACA 90/4885NTRK1 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.